We are live on ! Find out more
RLMD icon

Relmada Therapeutics
RLMD

82 hedge funds and large institutions have $335M invested in Relmada Therapeutics in 2021 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 19 increasing their positions, 26 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,377% more call options, than puts

Call options by funds: $17M | Put options by funds: $1.15M

20% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 10

12% more capital invested

Capital invested by funds: $298M → $335M (+$36.7M)

3% more funds holding

Funds holding: 80 → 82 (+2)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0.4% less ownership

Funds ownership: 57.33% → 56.93% (-0.4%)

27% less repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 26

Holders
82
Holders Change
+2
Holders Change %
+2.5%
% of All Funds
1.44%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
12
Increased
19
Reduced
26
Closed
10
Calls
$17M
Puts
$1.15M
Net Calls
+$15.8M
Net Calls Change
+$9.14M

Top Buyers

Rank Fund Capital Flow
1
IC
Ikarian Capital
Texas
+$10.2M
2
VA
VR Adviser
New York
+$6.46M
3
CAC
Cowen and Company
New York
+$5.84M
4
SSA
Schonfeld Strategic Advisors
New York
+$1.91M
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$1.74M

Top Sellers

Rank Fund Capital Flow
1
Invesco
Invesco
Georgia
-$8.57M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$3.94M
3
ACP
Acuta Capital Partners
California
-$3.85M
4
Wells Fargo
Wells Fargo
California
-$1.08M
5
Aviva
Aviva
United Kingdom
-$1.08M
Name Holding Trade Value Shares
Change 		Change in
Stake
UBS AM
51
UBS AM
Illinois
$225K – – –
Millennium Management
52
Millennium Management
New York
$224K -$649K -18,561 -74%
Creative Planning
53
Creative Planning
Kansas
$224K +$223K +6,375 New
Group One Trading
54
Group One Trading
Illinois
$219K +$218K +6,220 New
ProShare Advisors
55
ProShare Advisors
Maryland
$217K +$216K +6,165 New
CM
56
Caption Management
Oklahoma
$208K +$206K +5,889 New
OQS
57
Occudo Quantitative Strategies
Florida
$201K -$35.2K -1,007 -15%
DekaBank Deutsche Girozentrale
58
DekaBank Deutsche Girozentrale
Germany
$173K – – –
MLICM
59
Metropolitan Life Insurance Company (MetLife)
New York
$164K – – –
TIM
60
Tortoise Investment Management
New York
$153K – – –
Parallax Volatility Advisers
61
Parallax Volatility Advisers
California
$129K +$128K +3,670 New
SL
62
Savior LLC
Massachusetts
$123K +$122K +3,500 New
DMK
63
David M. Knott
$106K – – –
Legal & General Group
64
Legal & General Group
United Kingdom
$76K -$3.22K -92 -4%
TRCT
65
Tower Research Capital (TRC)
New York
$63K +$21.7K +620 +53%
Citigroup
66
Citigroup
New York
$62K -$96.1K -2,748 -61%
HCP
67
Hexagon Capital Partners
Arkansas
$56K – – –
AIP
68
Ameritas Investment Partners
Nebraska
$44K – – –
Morgan Stanley
69
Morgan Stanley
New York
$41K -$366K -10,462 -90%
Canada Life
70
Canada Life
Manitoba, Canada
$29K – – –
CG
71
Cutler Group
California
$24K +$18.9K +540 +338%
Bank of Montreal
72
Bank of Montreal
Ontario, Canada
$15K -$64.9K -1,854 -81%
PCM
73
Penserra Capital Management
California
$13K -$175 -5 -1%
Osaic Holdings
74
Osaic Holdings
Arizona
$12K – – –
Macquarie Group
75
Macquarie Group
Australia
$4K -$1.92K -55 -32%
1 2
3
4

RLMD Hedge Fund Activity: Q1 2021 in Review

82 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Relmada Therapeutics (RLMD) for Q1 2021, worth a combined $335M — up 12% from $298M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new RLMD positions and 10 closed out — a net gain of 2 holders — while 19 added to existing stakes and 26 trimmed.

The largest buyer was Ikarian Capital, opening a new position worth an estimated $10.2M. The largest seller was Invesco, exiting entirely with an estimated $8.57M sold.

  • 82 institutional investors held Relmada Therapeutics (RLMD) as of Q1 2021, up from 80 in Q4 2020.
  • Funds reported $335M of Relmada Therapeutics stock for Q1 2021, up 12% quarter-over-quarter.
  • 12 funds opened new Relmada Therapeutics positions in Q1 2021 and 10 closed out, a net change of +2 holders.
  • The largest Relmada Therapeutics buyer in Q1 2021 was Ikarian Capital, an estimated $10.2M added.
  • The largest Relmada Therapeutics seller in Q1 2021 was Invesco, an estimated $8.57M sold.

Based on aggregated 13F filings for Q1 2021.